Skip to main content
. 2019 Mar 6;2019:2473652. doi: 10.1155/2019/2473652

Figure 3.

Figure 3

The stability and diagnostic accuracy of circSMARCA5 for GC. (a) The qRT-PCR assay was used to show the abundance of circSMARCA5 and SMARCA5 mRNAs in SGC7901 treated with actinomycin D. (b) circSMARCA5 and SMARCA5 mRNA expression levels were examined by qRT-PCR after treatment with RNase R in SGC7901. (c) No statistically significant difference was observed in circSMARCA5 expression between plasma samples treated with three freeze-thaw cycles and the control group. (d) There was no difference of circSMARCA5 expression when plasma was incubated at room temperature for 0, 12, and 24 h. (e) The expression level of plasma circSMARCA5 was lower in GC patients than in healthy controls. (f) The area under the ROC curve (AUC) was 0.806. Data are shown as mean ± S.E.M.; ∗∗∗P < 0.001.